Imatilek (Imatinib)

Imatinib blocks the ATP‑binding pocket of several tyrosine kinases, most notably BCR‑ABL, c‑KIT, and PDGFR. By preventing phosphorylation, it stops downstream signaling pathways that promote cell division and survival, leading to reduced proliferation of cancer cells and, in many cases, induction of apoptosis.

The dose of Imatilek is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. Dosage adjustments may be required during treatment, and the prescriber will provide detailed instructions.

Imatilek is classified as a prescription‑only medication and should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians typically advise women of child‑bearing potential to use effective contraception and discuss any breastfeeding plans with their healthcare provider.

To request Imatilek, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatilek (imatinib) was the first BCR‑ABL inhibitor approved and remains a standard of care for CML and Ph+ ALL. Compared with newer agents, it has a well‑characterized safety profile and extensive clinical experience, though some newer inhibitors may offer activity against additional resistance mutations. Choice of therapy depends on disease characteristics and physician judgment.

Imatilek should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture and direct light, and store them out of reach of children. Do not refrigerate or freeze the product.

Imatilek is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but consistency with meals helps maintain stable absorption. Patients should follow the dosing schedule prescribed by their healthcare professional and not alter the regimen without medical advice.

Serious adverse events linked to Imatilek include hepatotoxicity, cardiotoxicity such as reduced left ventricular ejection fraction, and severe neutropenia that can predispose to infections. Patients should be monitored regularly for liver enzymes, cardiac function, and blood counts to detect these risks early.

Imatilek is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inducers that could markedly reduce drug exposure. The prescriber will assess suitability before initiating therapy.